Skip to main content
Premium Trial:

Request an Annual Quote

Sweden's SciLifeLab Joins Illumina Genome Network

NEW YORK (GenomeWeb News) – Illumina today announced that Science for Life Laboratory has joined the Illumina Genome Network.

SciLifeLab, headquartered in Sweden, is the first IGN partner in Europe and the thirteenth partner in the Illumina program. It will begin a national large-scale population sequencing program aimed at identifying genetic causes of human diseases, Illumina said.

"We now have the opportunity to offer an even larger capacity of high-throughput sequencing to researchers from all over Sweden," Joakim Lundeberg, professor of gene technology at KTH Royal Institute of Technology and director of the National Genomics Infrastructure at SciLifeLab, said in a statement. "In the research program we are about to launch, we aim to sequence more than 1,000 human genomes using the Illumina systems."

IGN connects researchers who need large-scale, whole-genome sequencing with institutions providing the service. Each IGN partner has completed Illumina's certified service provider certification and possesses at least 10 of the company's high-throughput sequencing platforms.

IGN partners include the Broad Institute, McGill University, Cold Spring Harbor Laboratory, the New York Genome Center, and Peking University, among others.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.